Life Sciences Tools and Services
Company Overview of SciFluor Life Sciences, LLC
SciFluor Life Sciences, LLC provides a fluorine based technology for therapeutics to improve drug profiles and to better understand how drugs are working in the body. It offers fluorination methods and technologies that enable the rapid, efficient synthesis of novel 18F tracers for empowered PET imaging. The company also provides develops Fluoropeutics, a fluorine-enabled development candidate for targeting a range of therapeutic indications, including central nervous system disorders, infectious diseases, cardiovascular and metabolic diseases, and oncology. SciFluor Life Sciences, LLC was founded in 2011 and is based in Boston, Massachusetts.
33 Arch Street
Boston, MA 02110
Founded in 2011
Key Executives for SciFluor Life Sciences, LLC
Founder and Chief Scientific Advisor
Director of Chemistry and Founder
Vice President of Business Development
Vice President and General Manager of Imaging
Compensation as of Fiscal Year 2014.
SciFluor Life Sciences, LLC Key Developments
SciFluor Life Sciences Names William Koster as Chairman of the Board
Apr 22 15
SciFluor Life Sciences named William Koster, PhD, a seasoned executive in drug discovery research and early clinical development, as Chairman of the Board. Koster previously served as President and Chief Executive Officer of Neurogen Corp. He also spent 30 years with Bristol-Myers Squibb Co. in various roles that included Senior Vice President overseeing worldwide drug discovery research and early clinical development through Phase 2a.
SciFluor Life Sciences, LLC Presents at BioPharm America 2013, Sep-18-2013 09:30 AM
Sep 17 13
SciFluor Life Sciences, LLC Presents at BioPharm America 2013, Sep-18-2013 09:30 AM. Venue: Westin Boston Waterfront Hotel, Boston, Massachusetts, United States. Speakers: Arthur Hiller, CEO.
SciFluor Life Sciences, LLC Presents New Preclinical Data for SF0034, a Novel Potassium Channel Opener for Treatment of Partial-Onset Seizure
Jun 25 13
SciFluor Life Sciences, LLC presented new preclinical data for SF0034, a novel potassium channel opener for the treatment of partial-onset seizure. Results show that SF0034 demonstrated a five-fold increase in potency, improved selectivity and a favorable pharmacological profile in a series of in vitro and in vivo preclinical models compared to ezogabine, a therapy currently approved in the U.S. and other global markets for the treatment of partial-onset seizure. SF0034 is one of the lead compounds in the expanding SciFluor portfolio of Fluoropeutics(TM). SciFluor scientists have discovered small-molecule new chemical entities (NCEs) by strategically introducing fluorine or fluorine groups into the molecular structure of known compounds directed toward precedented biological targets. SciFluor utilizes the incorporation of fluorine to create drugs with improved pharmacological profiles that provide important benefits over existing therapies. SF0034 was discovered by incorporating fluorine into ezogabine, an approved treatment for partial-onset seizure that must be administered three times a day. Data show that SF0034 is five times more potent with decreased QTc liabilities and a more balanced excretion pro le. In addition, SF0034 is less active at the potassium channel that causes urinary retention, potentially alleviating a key side effect of ezogabine.
Similar Private Companies By Industry
Recent Private Companies Transactions
April 22, 2015